TGV-Biomed is focused on the development of novel, diagnostics to select better treatments being evaluated for treating diabtetic foot ulcers. We have made life-changing breakthrough discoveries that can bring therapy of these infections to a new level of efficacy. It is our responsibility to accelerate way from our innovation to medicines thus new therapeutics not be late and be on time enhancing and extending patients’ lives.
Mul-1867 is a first-in-class antimicrobial agent, structurally and functionally distinct from all existing antimicrobials. Mul-1867 has been shown to have fast-acting bactericidal, fungicidal and virucidal activity against the most resistant isolates.
Mul-1867 targets biofilm-associated infections caused by a number of bacteria and fungi, including P.aeruginosa, S.aureus (including MRSA/VISA/VRSA), H.influenzae, Aspergillus spp., Candida spp., etc.